Nadia Spiccia is an associate in Kirkland’s Intellectual Property Litigation Practice Group in London. With over 12 years’ experience supporting global pharma/biopharma and a background in chemistry, Nadia leverages her legal and technical experience to provide strategic counselling.
Nadia’s practice focuses on complex cross border and multijurisdictional life sciences patent disputes requiring significant coordination across multiple forums at both first instance and on appeal including in Australia, Asia, Europe, UK, LATAM and Middle East.
Nadia provides IP leadership for pharma/biopharm product development and commercialisation in global markets – from initial scoping through to post-launch. She has developed and implemented global IP strategies that align with commercial objectives for more than 8 years at multi-national pharma/biopharma companies giving her first-hand experience in and knowledge of the industry.
Her expertise includes freedom-to-operate (FTO) patent assessments, ‘front end’ procurement and licensing agreements, IP strategy design such as patent circumvention/product redesign and alignment with regulatory procedures, patent prosecution, ex-US patent oppositions and devising, coordinating and executing patent strategies for complex multijurisdictional disputes (including complex damages inquiries) at a pan-European and global scale in the pharma/biopharma field.
Prior to joining Kirkland, Nadia was Head of Patent Litigation - ex NA at Sandoz responsible for the launch and litigation of Sandoz’s small molecule and biosimilars worldwide apart from North America. Prior to this Nadia was Head of Legal and Company Secretary - ANZ for Mylan (now Viatris).
Nadia was recognised as a Notable Practitioner - IP Stars by Managing IP in the 2021 edition, Corporate IP Star – Europe by Managing IP in the 2019-2020 editions and a Leading In-House Intellectual Property & TMT Lawyers – Australia by Doyle’s Guide in the 2019-2020 editions.
